Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Treatment of stroke using isolated placental cells

A cell and placenta technology, applied in the field of stroke treatment using isolated placental cells, can solve the problem of no effective treatment for stroke

Pending Publication Date: 2016-07-27
ANTHROGENESIS LLC
View PDF14 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] There is no effective therapy for stroke

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of stroke using isolated placental cells
  • Treatment of stroke using isolated placental cells
  • Treatment of stroke using isolated placental cells

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0225] 5.7 Preparation of placental cell bank

[0226] Isolated cells from postpartum placenta, e.g., those described in Section 5.4.2 above, can be cultured in a number of different ways to prepare a set of batches, e.g., wherein each batch is a plurality of individually administrable doses . Such a batch can be obtained, for example, from cells from placental perfusate or from cells from enzymatically digested placental tissue. A batch of placental cells obtained from a plurality of placentas can be arranged in a separate placental cell bank, eg, for long-term storage. Typically, placental cells in plastic-adherent tissue culture are obtained from primary cultures of placental material to form seed cultures, which are expanded under controlled conditions to form approximately doublings of cell populations. A batch is preferably derived from a single placental tissue, but can be derived from multiple placental tissues.

[0227] In one embodiment, a placental cell batch is ...

Embodiment 1

[0297] 6.1 Example 1: Intracranial Administration of Isolated Placental Cells for Stroke

[0298] This example demonstrates the efficacy of administering isolated placental cells in the treatment of conditions associated with disruption of blood flow in or around the brain or CNS.

[0299] CD34 is obtained by enzymatic digestion with about 1 to about 2 mg / ml of collagenase I, e.g., for 30 minutes, followed by enzymatic digestion with about 0.25% trypsin at 37° C. for 10 minutes. - , CD10 + , CD105 + 、CD200 + Placental cells in plastic-adherent tissue culture. Sprague-Dawley rats were used as a stroke model. The rat is an established model animal used to study the outcome of stroke and the effect of different therapies on stroke symptoms. See, eg, Chen et al., "AModel of Focal Ischemic Stroke in the Rat: Reproducible Extensive Cortical Infarction", Stroke 17(4):738-743 (1986). Ten animals were used for each condition.

[0300] MCA stroke surgery: All surgical procedures ...

Embodiment 2

[0310] 6.2 Example 2: Treatment of Stroke Using Intravenously Administered Isolated Placental Cells

[0311] This example demonstrates the efficacy of intravenous administration of isolated placental cells in the treatment of conditions associated with disruption of blood flow in or around the brain or CNS, such as the treatment of hypoxic or hypoxic injury. For example, the results presented here demonstrate that intravenous administration of viable human placental cells promotes dose-dependent behavioral recovery in motor and neurological assays in animals administered placental cells compared to animals receiving non-viable human placental cells .

[0312] Isolated CD34 was obtained by enzymatic digestion as described elsewhere herein - , CD10 + , CD105 + 、CD200 + Placental cells in plastic-adherent tissue culture. Sprague-Dawley rats were used as a stroke model, and the middle arteries were occluded as described in Example 1 above. On day 2 after blocking, recipient ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and / or compositions comprising placental stem cells. The invention also provides the application of isolated human adherent placental cells in the production for the treatment of an individual having a disruption in the flow of blood in or around the brain.

Description

[0001] This application is a divisional application of a Chinese invention patent application with an application date of August 20, 2009, an application number of 200980141316.X, and a title of "Using Isolated Placental Cells to Treat Stroke". This application claims priority to US Provisional Patent Application No. 61 / 090,565, filed August 20, 2008, which is hereby incorporated by reference in its entirety. field of invention [0002] The present invention provides the use of isolated placental cells, such as placental pluripotent cells, populations of said isolated placental cells, and / or compositions comprising said cells to treat patients with hypoxic injury, or disrupted blood flow in or around the brain. The method of an individual having symptoms or deficiencies such as neurological impairment due to disruption of blood flow in or around the brain. Background of the invention [0003] Stroke, also known as "cerebral stroke", cerebrovascular injury (CVA) or acute isch...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/50C12N5/073A61P25/00A61P9/10A61K35/12
CPCA61K35/50C12N5/0605A61K35/12A61P1/04A61P1/08A61P11/00A61P11/02A61P15/00A61P21/00A61P21/02A61P25/00A61P25/02A61P25/04A61P25/14A61P27/00A61P27/02A61P27/16A61P9/00A61P9/02A61P9/10A61K31/10A61K45/06
Inventor 安迪·查特林阿贾伊·帕尔
Owner ANTHROGENESIS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com